Trial Profile
A Multicentre, Retrospective Study Investigating the Efficacy and Safety of Ruxolitinib in Patients with Myelofibrosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 26 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.